サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1451670

治療用ワクチン市場レポート：タイプ別、疾患タイプ別、技術別、流通チャネル別、地域別、2024-2032

Therapeutic Vaccines Market Report by Type, Disease Type, Technology, Distribution Channel, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 147 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
治療用ワクチン市場レポート：タイプ別、疾患タイプ別、技術別、流通チャネル別、地域別、2024-2032
出版日: 2024年03月02日
発行: IMARC
ページ情報: 英文 147 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の治療用ワクチン市場規模は2023年に313億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて9.5%の成長率（CAGR）を示し、2032年までに714億米ドルに達すると予測しています。治療選択肢が限られている疾患の有病率の上昇、低侵襲手術（MIS）に対する個人の嗜好の高まり、製薬会社、研究機関、学界間のパートナーシップの拡大は、市場を推進している主な要因の一部です。

治療用ワクチンは、免疫治療用ワクチンとしても知られ、患者の免疫系を刺激し、特定の疾患を標的として闘うように設計された医療介入の一種です。化学療法のような従来の治療法に比べて副作用が少ないです。健康な細胞に大きなダメージを与えることなく免疫系を刺激します。初回治療後の疾患再発の可能性を減少させる。化学療法や分子標的治療などの他の治療法と併用することで相乗効果が得られます。ヒト免疫不全ウイルス（HIV）やB型肝炎のような慢性感染症では、免疫反応を高めることでウイルス量をコントロールし、病気の進行を最小限に抑えることができます。

ある種のがんや希少疾患など、治療選択肢が限られている疾患の有病率が上昇していることが、ワクチンのような革新的な治療アプローチに対する需要を喚起しています。さらに、様々な慢性疾患に罹患しやすい高齢化人口の増加が、治療用ワクチンのような新規治療法の必要性を高めています。これとは別に、各国政府は免疫療法やワクチン分野の研究開発（R&D）に対して支援政策や助成金、資金援助を行っています。さらに、非侵襲的または低侵襲的な治療法に対する個人の嗜好の高まりが、治療用ワクチンの需要を牽引しています。さらに、製薬会社、研究機関、学界のパートナーシップが、治療用ワクチンの開発と商業化を加速させています。

治療用ワクチン市場の動向と促進要因：

慢性疾患の有病率の上昇

がん、自己免疫疾患、感染症など、様々な慢性疾患の有病率の上昇は、市場成長を促進する重要な要因のひとつです。治療用ワクチンは、疾病に関連する抗原を認識し標的とする個人の免疫系を利用することで、有望な手段を提供します。これとは別に、個別化された医薬品に対する嗜好の高まりが市場にプラスの影響を与えています。これらのワクチンは、特定の疾患を標的とし、疾患管理に革命をもたらす可能性を秘めています。さらに、治療用ワクチンは疾患の再発リスクを低減し、患者の転帰と生活の質を高めることができます。

免疫学とバイオテクノロジーの進歩

免疫学とバイオテクノロジーの急速な進歩は、市場の見通しを明るいものにしています。これらの科学的進歩により、免疫系とその疾患に対する反応についての理解が再定義されつつあります。さらに、免疫学における飛躍的な進歩は、免疫チェックポイント、サイトカインシグナリング、抗原提示の複雑さを明らかにし、より効果的な治療用ワクチンの開発に弾みをつける知見を提供しています。これとは別に、mRNAベースのワクチン・プラットフォームや遺伝子編集技術を含むバイオテクノロジーの革新は、ワクチン設計と製造の展望を再構築しつつあります。さらに、ナノ粒子ベースのワクチンの出現は、抗原提示を制御し、免疫反応を増幅して治療効果を高める機会を提供しています。

精密医療へのシフト

精密医療へのシフトは、治療用ワクチン市場にプラスの影響を与えています。精密医療とは、患者中心のアプローチを具体化したもので、遺伝学、分子プロファイル、免疫学的マーカーといった個人の特徴に合わせて治療を調整するものです。このアプローチは、各患者の疾患の独自性を認め、治療結果の最適化を目指すものです。これとは別に、これらのワクチンは、患者ごとに異なる疾患特異的抗原を標的とすることで、がんのような疾患固有の不均一性に対処します。予測バイオマーカーの同定と革新的なバイオマーカー誘導戦略のイントロダクションは、これらの治療から恩恵を受ける可能性が最も高い患者を特定するため、好転反応の可能性を高める。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 世界の治療用ワクチン市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • 抗原ワクチン
    • 市場動向
    • 市場予測
  • 樹状細胞ワクチン
    • 市場動向
    • 市場予測
  • DNAワクチン
    • 市場動向
    • 市場予測
  • 腫瘍細胞ワクチン
    • 市場動向
    • 市場予測

第7章 市場内訳：疾患タイプ別

  • 自己免疫疾患ワクチン
    • 市場動向
    • 市場予測
  • 中毒ワクチン
    • 市場動向
    • 市場予測
  • 神経疾患ワクチン
    • 市場動向
    • 市場予測
  • 感染症ワクチン
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：技術別

  • 自己免疫ワクチン
    • 市場動向
    • 市場予測
  • 同種ワクチン
    • 市場動向
    • 市場予測

第9章 市場内訳：流通チャネル別

  • 病院薬局
    • 市場動向
    • 市場予測
  • 小売薬局
    • 市場動向
    • 市場予測
  • オンライン薬局
    • 市場動向
    • 市場予測

第10章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Agenus Inc.
    • Argos Therapeutics Inc.
    • Bavarian Nordic A/S
    • Cel-Sci Corporation
    • CSL Limited
    • Emergent Biosolutions Inc.
    • GSK plc
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Sanofi S.A.
図表

List of Figures

  • Figure 1: Global: Therapeutic Vaccines Market: Major Drivers and Challenges
  • Figure 2: Global: Therapeutic Vaccines Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Therapeutic Vaccines Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Therapeutic Vaccines Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Therapeutic Vaccines Market: Breakup by Disease Type (in %), 2023
  • Figure 6: Global: Therapeutic Vaccines Market: Breakup by Technology (in %), 2023
  • Figure 7: Global: Therapeutic Vaccines Market: Breakup by Distribution Channel (in %), 2023
  • Figure 8: Global: Therapeutic Vaccines Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Therapeutic Vaccines (Antigen Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Therapeutic Vaccines (Antigen Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Therapeutic Vaccines (Dendritic Cell Vaccine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Therapeutic Vaccines (Dendritic Cell Vaccine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Therapeutic Vaccines (DNA Vaccine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Therapeutic Vaccines (DNA Vaccine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Therapeutic Vaccines (Tumor Cell Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Therapeutic Vaccines (Tumor Cell Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Therapeutic Vaccines (Autoimmune Disease Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Therapeutic Vaccines (Autoimmune Disease Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Therapeutic Vaccines (Addiction Vaccine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Therapeutic Vaccines (Addiction Vaccine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Therapeutic Vaccines (Neurological Disease Vaccine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Therapeutic Vaccines (Neurological Disease Vaccine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Therapeutic Vaccines (Infectious Disease Vaccine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Therapeutic Vaccines (Infectious Disease Vaccine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Therapeutic Vaccines (Other Disease Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Therapeutic Vaccines (Other Disease Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Therapeutic Vaccines (Autologous Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Therapeutic Vaccines (Autologous Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Therapeutic Vaccines (Allogeneic Vaccine) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Therapeutic Vaccines (Allogeneic Vaccine) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Therapeutic Vaccines (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Therapeutic Vaccines (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Therapeutic Vaccines (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Therapeutic Vaccines (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Therapeutic Vaccines (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Therapeutic Vaccines (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: North America: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: North America: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: United States: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: United States: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Canada: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Canada: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Asia-Pacific: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Asia-Pacific: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: China: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: China: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Japan: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Japan: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: India: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: India: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: South Korea: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: South Korea: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Australia: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Australia: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Indonesia: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Indonesia: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Others: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Others: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Europe: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Europe: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Germany: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Germany: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: France: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: France: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: United Kingdom: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: United Kingdom: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Italy: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Italy: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Spain: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Spain: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Russia: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Russia: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Others: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Others: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Latin America: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Latin America: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Brazil: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Brazil: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Mexico: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Mexico: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Others: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Others: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Middle East and Africa: Therapeutic Vaccines Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Middle East and Africa: Therapeutic Vaccines Market: Breakup by Country (in %), 2023
  • Figure 85: Middle East and Africa: Therapeutic Vaccines Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Global: Therapeutic Vaccines Industry: SWOT Analysis
  • Figure 87: Global: Therapeutic Vaccines Industry: Value Chain Analysis
  • Figure 88: Global: Therapeutic Vaccines Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Therapeutic Vaccines Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Therapeutic Vaccines Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Therapeutic Vaccines Market Forecast: Breakup by Disease Type (in Million US$), 2024-2032
  • Table 4: Global: Therapeutic Vaccines Market Forecast: Breakup by Technology (in Million US$), 2024-2032
  • Table 5: Global: Therapeutic Vaccines Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 6: Global: Therapeutic Vaccines Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Therapeutic Vaccines Market: Competitive Structure
  • Table 8: Global: Therapeutic Vaccines Market: Key Players
目次
Product Code: SR112024A6496

The global therapeutic vaccines market size reached US$ 31.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 71.4 Billion by 2032, exhibiting a growth rate (CAGR) of 9.5% during 2024-2032. The rising prevalence of diseases with limited treatment options, increasing preferences of individuals for minimally invasive surgeries (MIS), and the growing partnerships between pharmaceutical companies, research institutions, and academia are some of the major factors propelling the market.

Therapeutic vaccines, also known as treatment vaccines or immunotherapeutic vaccines, are a type of medical intervention designed to stimulate the immune system of patients to target and combat specific diseases. They have fewer side effects compared to traditional treatments like chemotherapy. They stimulate the immune system without causing extensive damage to healthy cells. They help reduce the likelihood of disease recurrence after initial treatment. They can be combined with other treatments, such as chemotherapy or targeted therapies, to create a synergistic effect. They aid in managing chronic infections like human immunodeficiency viruses (HIV) and hepatitis B by enhancing the immune response to control the viral load and minimize disease progression.

The rising prevalence of diseases with limited treatment options, such as certain types of cancers and rare disorders, is catalyzing the demand for innovative therapeutic approaches like vaccines. Additionally, the increasing aging population aging population, which is highly susceptible to various chronic ailments is driving the need for novel treatment modalities like therapeutic vaccines. Apart from this, governments of various countries are offering supportive policies, grants, and funding for research and development (R&D) in the field of immunotherapy and vaccines. Furthermore, the rising preferences of individuals for non-invasive or minimally invasive treatment options are driving the demand for therapeutic vaccines. Moreover, partnerships between pharmaceutical companies, research institutions, and academia are accelerating the development and commercialization of therapeutic vaccines.

Therapeutic Vaccines Market Trends/Drivers:

Rising prevalence of chronic diseases

The rising prevalence of various chronic health conditions, such as cancer, autoimmune disorders, and infectious diseases represents one of the key factors propelling the market growth. Therapeutic vaccines offer a promising avenue by harnessing the immune system of individuals to recognize and target disease-associated antigens. Apart from this, rising preferences for personalized medicines is positively influencing the market. These vaccines hold the potential to target specific disorders and revolutionize disease management. Moreover, therapeutic vaccines can reduce the risk of disease recurrence, enhancing patient outcomes and quality of life.

Advancements in immunology and biotechnology

The rapid advancements in immunology and biotechnology are creating a positive market outlook. These scientific advancements are redefining our understanding of the immune system and its responses to diseases. Additionally, breakthroughs in immunology are unveiling the intricacies of immune checkpoints, cytokine signaling, and antigen presentation, providing insights that fuel the development of more effective therapeutic vaccines. Apart from this, biotechnology innovations, including mRNA-based vaccine platforms and gene editing techniques, are reimagining the landscape of vaccine design and production. Furthermore, the advent of nanoparticle-based vaccines offers opportunities for controlled antigen presentation, amplifying the immune reaction for heightened therapeutic efficacy.

Shift towards precision medicine

The shift towards precision medicine is positively influencing the therapeutic vaccines market. Precision medicine embodies a patient-centric approach, tailoring treatments to individual characteristics such as genetics, molecular profiles, and immunological markers. This approach acknowledges the uniqueness of the disease of each patient and seeks to optimize therapeutic outcomes. Apart from this, these vaccines address the inherent heterogeneity of diseases like cancer by targeting disease-specific antigens that are distinct to each patient. The identification of predictive biomarkers and the introduction of innovative biomarker-guided strategies enhance the likelihood of positive responses, as they identify patients who are most likely to benefit from these treatments.

Therapeutic Vaccines Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global therapeutic vaccines market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on type, disease type, technology and distribution channel.

Breakup by Type:

Antigen Vaccines

Dendritic Cell Vaccine

DNA Vaccine

Tumor Cell Vaccines

Tumor cell vaccines hold the largest market share

The report has provided a detailed breakup and analysis of the market based on the type. This includes antigen vaccines, dendritic cell vaccine, DNA vaccine, and tumor cell vaccines. According to the report, tumor cell vaccines represented the largest market segment as they are specifically designed to target cancer cells, offering a highly focused approach to treatment. This specificity minimizes damage to healthy cells, reducing adverse effects commonly associated with traditional therapies. Additionally, they stimulate the immune system to remember cancer cells, enabling the body to respond more effectively if the cancer recurs. This immune memory contributes to longer-lasting treatment outcomes. Apart from this, they can be used in combination with other treatments like checkpoint inhibitors or chemotherapy, creating a synergistic effect that enhances the overall treatment response. Furthermore, these vaccines help reduce the likelihood of tumor resistance that can occur with single-target therapies.

Breakup by Disease Type:

Autoimmune Disease Vaccines

Addiction Vaccine

Neurological Disease Vaccine

Infectious Disease Vaccine

Others

Autoimmune disease vaccines represent the largest market segment

A detailed breakup and analysis of the market based on the disease type has also been provided in the report. This includes autoimmune disease vaccines, addiction vaccines, neurological disease vaccine, infectious disease vaccine, and others. According to the report, autoimmune disease vaccines dominates the market due to the rising prevalence of autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, and lupus across the globe. Additionally, these vaccines offer a potential alternative by stimulating immune tolerance, reducing the need for immunosuppression. Apart from this, they can be customized based on individual patient profiles, considering genetic and immunological factors. This aligns with the growing trend towards personalized medicine, enhancing treatment effectiveness. Apart from this, positive outcomes from clinical trials of autoimmune disease vaccines, coupled with advancements in immunology research, validate their potential to address unmet medical needs.

Breakup by Technology:

Autologous Vaccines

Allogeneic Vaccine

Autologous vaccines account for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on technology. This includes autologous vaccines and allogeneic vaccine. According to the report, autologous vaccines hold the largest market share as they are custom-made for each patient using their own cells, ensuring a personalized treatment strategy that aligns with the patient's unique disease profile and immune system. Apart from this, since autologous vaccines use the original cells of patients, there is a lower risk of immune rejection or adverse reactions compared to treatments that involve foreign agents. Furthermore, they help reduce toxicity concerns associated with traditional treatments like chemotherapy by targeting disease cells while sparing healthy cells. Moreover, autologous vaccines are well-suited to address the genetic and molecular heterogeneity often found in diseases like cancer.

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

A detailed breakup and analysis of the market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and online pharmacies.

Hospital pharmacies operate within healthcare facilities, which ensures direct access to patients undergoing treatments. They facilitate immediate availability, expert guidance, and seamless integration with medical care and aid in dispensing and administering therapeutic vaccines, especially for critical conditions requiring close medical supervision.

Retail pharmacies are widespread and easily accessible to the general population. They offer convenience and a wide range of healthcare products, including therapeutic vaccines. Additionally, they cater to diverse patient needs, making therapeutic vaccines more accessible to the masses.

Online pharmacies offer a convenient platform to purchase therapeutic vaccines remotely. They provide a wide selection, price comparisons, and home delivery, which are particularly advantageous for patients with mobility limitations or those seeking privacy.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest therapeutic vaccines market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share since the region has a well-developed healthcare infrastructure, comprising modern hospitals, research institutions, and pharmaceutical companies, which accelerates research, development, and commercialization of therapeutic vaccines. Additionally, North America is a global hub for medical research and innovation, housing renowned universities, research centers, and biotechnology firms. Apart from this, regulatory agencies in North America, such as the U.S. Food and Drug Administration (FDA) and Health Canada, maintain rigorous standards for drug and vaccine approvals. Moreover, North America has a well-established clinical trial ecosystem, which facilitates the efficient testing and validation of therapeutic vaccines. The availability of diverse patient populations and expert medical professionals expedites the trial process.

Competitive Landscape:

Companies are investing in research to identify novel antigens and develop innovative vaccine platforms, which include exploring cutting-edge technologies like mRNA-based vaccines, viral vectors, and personalized vaccine approaches. Additionally, many vaccine developers are conducting rigorous clinical trials to evaluate the safety and efficacy of their products. Furthermore, they are working closely with regulatory agencies to obtain approvals for their therapeutic vaccines. This involves compiling comprehensive data from clinical trials to demonstrate safety, efficacy, and manufacturing quality. Moreover, many leading companies are investing in infrastructure and technologies to ensure consistent and efficient vaccine production.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Agenus Inc.

Argos Therapeutics Inc.

Bavarian Nordic A/S

Cel-Sci Corporation

CSL Limited

Emergent Biosolutions Inc.

GSK plc

Merck & Co. Inc.

Pfizer Inc.

Sanofi S.A.

Recent Developments:

In July 2023, Sanofi S.A. announced that it has received marketing authorization for Dupixent(R) (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis.

In August 2023, the European Commission approved Pfizer Inc's ABRYSVO(TM) to help protect infants through maternal immunization and older adults from RSV.

In August 2023, Merck & Co. Inc. announced that LYNPARZA(R) (olaparib)Plus Abiraterone and Prednisolone are approved in Japan for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.

Key Questions Answered in This Report

  • 1. What was the size of the global therapeutic vaccines market in 2023?
  • 2. What is the expected growth rate of the global therapeutic vaccines market during 2024-2032?
  • 3. What are the key factors driving the global therapeutic vaccines market?
  • 4. What has been the impact of COVID-19 on the global therapeutic vaccines market?
  • 5. What is the breakup of the global therapeutic vaccines market based on the type?
  • 6. What is the breakup of the global therapeutic vaccines market based on the disease type?
  • 7. What is the breakup of the global therapeutic vaccines market based on the technology?
  • 8. What are the key regions in the global therapeutic vaccines market?
  • 9. Who are the key players/companies in the global therapeutic vaccines market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Therapeutic Vaccines Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Antigen Vaccines
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Dendritic Cell Vaccine
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 DNA Vaccine
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Tumor Cell Vaccines
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Autoimmune Disease Vaccines
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Addiction Vaccine
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Neurological Disease Vaccine
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Infectious Disease Vaccine
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Technology

  • 8.1 Autologous Vaccines
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Allogeneic Vaccine
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Agenus Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Argos Therapeutics Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Bavarian Nordic A/S
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
    • 15.3.4 Cel-Sci Corporation
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 CSL Limited
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Emergent Biosolutions Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 GSK plc
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Merck & Co. Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Pfizer Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Sanofi S.A.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis